Skip to main content
OpenTrials
Completed

NCT Number: NCT02413008

A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors (NSAIs) in the adjuvant setting and symptoms of vaginal atrophy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vaginal Atrophy Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U., L'Hospitalet de Llobregat, Barcelona, Spain

Loading trial locations.

About this study

This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study.

In the setting of postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors (AIs) is the most effective and well-studied therapy. Vaginal dryness is one of the most frequently reported symptom caused by this adjuvant therapy which may lead to a reduced adherence in breast cancer women.

This study will explore the safety of 0.005% estriol vaginal gel in this oncological context, to demonstrate that this medicinal product is a safe option to treat the vaginal atrophy caused by AIs, without a clinically relevant influence in gonadotropins or systemic estrogen levels.

The main objective is to evaluate the levels of Follicle Stimulating Hormone (FSH) after treatment with 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors (NSAIs) in the adjuvant setting and symptoms of vaginal atrophy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent prior to beginning specific protocol procedures.
  • Patients must have histological confirmation of breast adenocarcinoma with stage I-IIIA, documented at a local pathology department.
  • The breast tumors must be estrogen-receptor positive and/or progesterone receptor positive (≥1% of stained tumor cells by Immunohistochemistry (IHC) as determined by the local laboratory) with any Human Epidermal Growth Factor Receptor 2(HER2) status.
  • Postmenopausal status defined as: 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 Milli-international units per milliliter (mIU/ml) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  • Patient must be receiving the non-steroidal aromatase inhibitors anastrozole or letrozole as breast cancer treatment in the adjuvant setting for a minimum of 6 months.
  • Women suffering from moderate to severe vaginal dryness according to the FDA guidelines for drug development in postmenopausal women (Center for Drug Evaluation and Research, (CDER) Jan 2003). A moderate symptom will be considered if the symptom is present, bothersome and annoying, and a severe symptom will be considered if the symptom is present, bothersome and annoying, and interferes with the normal patient activity.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  • Adequate bone marrow as defined by the following laboratory values:
  • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.
  • Platelets (plt) ≥ 100 x 109/L.
  • Hemoglobin (Hgb) ≥ 10 g/dl.
  • Patient has adequate organ function as defined by the following laboratory values:
  • Serum creatinine ≤ 1.5 x Upper Limit of Normal (ULN).
  • Bilirubin ≤ 1.5 × ULN.
  • Alkaline phosphatase ≤ 2 × ULN.
  • Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 × ULN.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

  • Stage IIIB-IV breast cancer or bilateral breast cancer.
  • Treatment with any other current anti-tumoral therapy (chemotherapy, anti-Her2…etc) besides the NSAI. Pamidronate or Alendronate are permitted.
  • Prior history of other malignancy within 5 years of study entry, aside from non-melanoma skin cancer or carcinoma-in-situ of the uterine cervix adequately treated.
  • Postmenopausal uterine bleeding. Vaginal bleeding of unknown etiology.
  • Patients with endometrial thickness equal to or greater than 4 mm measured by transvaginal ultrasound.
  • Patients who have received any type of vulvovaginal treatment in the 15 days prior to the start of the study.
  • Use of any hormone, natural (phytoestrogens) or herbal products for the treatment of menopausal symptoms within the last 3 months.
  • Current or previous history of thromboembolic disease or coagulopathies.
  • Severe cardiovascular or respiratory diseases in the previous 6 months.
  • Renal Impairment.
  • Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function).
  • Known human immunodeficiency virus infection.
  • Known hypersensitivity to NSAI.
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
  • Previous investigational treatment for any condition or participation in any clinical trial within 4 weeks of inclusion date.

Treatment and study plan

estriol

Drug

0.005% estriol vaginal gel

Other names: Blissel (estriol), Gelistrol (estriol)

Placebo

Drug

placebo vaginal gel

Primary outcomes

  1. Variation in Serum Levels of Follicle Stimulating Hormone (FSH)

    Time frame: from baseline to 12 weeks of treatment

    Change from Baseline (mean screening-baseline) to Week 12 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation)

Secondary outcomes

  1. Variation in Serum Levels of FSH at Week 1, Week 3 and Week 8

    Time frame: Change from baseline to week 1, week 3 and week 8

    Change from Baseline (mean screening-baseline) to Week 1, Week 3 and Week 8 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability ( screening-baseline variation)

  2. Variation in Serum Levels of Luteinizing Hormone (LH)

    Time frame: Change from baseline to week 1, week 3, week 8 and week 12

    Change from (mean screening-baseline) in plasma levels of LH to Week 1, Week 3, Week 8 and Week 12 in Serum Levels of LH compare to natural physiological variability ( screening-baseline variation)

  3. Variation in Plasma Levels of Estriol

    Time frame: Change from baseline to week 1, week 3, week 8 and week 12

    Change in plasma levels of estriol at weeks 1, 3, 8 and 12 compared to baseline

  4. Variation in Plasma Levels of Estradiol

    Time frame: Change from baseline to week 1, week 3, week 8 and week 12

    Change in plasma levels of estradiol at weeks 1, 3, 8 and 12 compared to baseline.

  5. Variation in Plasma Levels of Estrona

    Time frame: Change from baseline to week 1, week 3, week 8 and week 12

    Change in plasma levels of estrona at weeks 1, 3, 8 and 12 compared to baseline.

  6. Changes in Vaginal pH Between Baseline and Week 3 and Week 12

    Time frame: week 3 and week 12 vs baseline

    Measurement of vaginal pH on the vaginal secretion using a reactive strip and compare pH value between baseline and the diferent timepoints

  7. Changes in Dyspareunia

    Time frame: week 3 and week 12 vs baseline

    Changes in dyspareunia from baseline to week 3 and week 12 Each symptom will be scored in a numeric scale from 0 to 3, as shown 0 Absence. The symptom is not present

    • The symptom is of mild intensity, without interfering in the patient's activity
    • The symptom is of moderate intensity, causing obvious discomfort to the patient
    • The symptom is stated as very irritating and severe in intensity

  8. Change in Pruritus or Itching From Baseline to Week 3 and Week 12

    Time frame: Change from baseline to week 3 and week 12

    Change in pruritus or itching from baseline to week 3 and week 12

    Each symptom will be scored in a numeric scale from 0 to 3, as shown below:

    0 Absence. The symptom is not present

    • The symptom is of mild intensity, without interfering in the patient's activity
    • The symptom is of moderate intensity, causing obvious discomfort to the patient
    • The symptom is stated as very irritating and severe in intensity

  9. Changes in Vaginal Dryness

    Time frame: week 3 and week 12 vs baseline

    Change in vaginal dryness puntuation score from baseline to w3 and w12

    Each symptom will be scored in a numeric scale from 0 to 3, as shown below:

    0 Absence. The symptom is not present

    • The symptom is of mild intensity, without interfering in the patient's activity
    • The symptom is of moderate intensity, causing obvious discomfort to the patient
    • The symptom is stated as very irritating and severe in intensity

  10. Changes in Total Score of Symptoms of Vaginal Atrophy

    Time frame: week 3 and week 12 vs baseline

    Changes in Symptoms of vaginal atrophy (vaginal dryness, dyspareunia and pruritus) at week 3 and week 12 vs baseline.

    Each symptom will be scored in a numeric scale from 0 to 3, as shown below:

    0 Absence. The symptom is not present

    • The symptom is of mild intensity, without interfering in the patient's activity
    • The symptom is of moderate intensity, causing obvious discomfort to the patient
    • The symptom is stated as very irritating and severe in intensity A Global Symptoms Score will be calculated by summing the intensities of all the three symptoms of vaginal atrophy in a certain time point, thus ranging between 0 and 9.

  11. Changes in Dryness of the Mucosa

    Time frame: week 3 and week 12 vs baseline

    It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:

    0 Absence. The sign is not present.

    • The sign is present and is considered a mild alteration
    • The sign is present and is considered a moderate alteration
    • The sign is present and is considered a severe alteration

  12. Changes in Fragility of the Mucosa [Time Frame: Week 3 and Week 12 vs Baseline]

    Time frame: from baseline to week 3 and 12

    It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:

    0 Absence. The sign is not present.

    • The sign is present and is considered a mild alteration
    • The sign is present and is considered a moderate alteration
    • The sign is present and is considered a severe alteration

  13. Changes in Vaginal Mucosa With Flattening of Folds or Thinning

    Time frame: week 3 and week 12 vs baseline

    It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:

    0 Absence. The sign is not present.

    • The sign is present and is considered a mild alteration
    • The sign is present and is considered a moderate alteration
    • The sign is present and is considered a severe alteration

  14. Changes in Total Score of Signs of Vaginal Atrophy Between Week 3 and Week 12 to Baseline

    Time frame: week 3 and week 12 vs baseline

    The signs evaluated Will be the following: vaginal mucosa with flattening of folds or thinning, dryness of the mucosa and Fragility of the mucosa.

    It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:

    0 Absence. The sign is not present.

    • The sign is present and is considered a mild alteration
    • The sign is present and is considered a moderate alteration
    • The sign is present and is considered a severe alteration A Total Signs Score will be calculated by summing the intensities of all the three signs of vaginal atrophy in a certain time point, thus ranging between 0 and 9.

  15. Changes in Vaginal Maturation Value

    Time frame: week 3 and week 12 vs baseline

    Vaginal cytology sample to evaluate the vaginal Maturation Value. For the cytologic evaluation, the number of parabasal, intermediate and superficial cells will be calculated in duplicate on 100 consecutive cells of vaginal cytology. The average of the two percentages obtained for each cell type will be calculated, which will serve to determine the maturation value (MV) based on the following formula:

    0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial).

Sponsors and collaborators

Lead sponsor

ITF Research Pharma, S.L.U.

Industry

Collaborators

  • Spanish Breast Cancer Research Group

Registry information

Official study title

A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

Acronym: BLISSAFE

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Apr 9, 2015
Registry last updated
Aug 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.